The majority of women with hormone receptor (HR)+, HER2– breast cancer respond to endocrine therapy, although acquired resistance is common. Now, data from a phase III trial demonstrate the efficacy of the potent α-isoform-specific phosphatidylinositol 3-kinase-α (PI3Kα) inhibitor alpelisib.
In this international, multicentre trial, a cohort of 572 patients with locally confirmed HR+, HER2– advanced-stage breast cancer, of whom 341 had confirmed PIK3CA alterations, were randomized (1:1) to receive alpelisib plus fulvestrant or placebo plus fulvestrant. Progression-free survival (PFS) specifically in patients with PIK3CA-mutant disease was the primary end point.
After a median follow-up duration of 20 months, patients in the alpelisib group with PIK3CA-mutant disease had a median PFS of 11.0 months versus 5.7 months in the placebo group (hazard ratio for disease progression or death 0.65, 95% CI 0.50–0.85; P < 0.001). This difference was not observed in comparisons of the outcomes of patients with PIK3CA-wild-type disease (median PFS 7.4 versus 5.6 months respectively, hazard ratio 0.85, 95% CI 0.58–1.25).
Grade 3 or 4 adverse events were observed in 64.4% and 11.6% of patients in the alpelisib group, versus 30.3% and 5.2% among those receiving placebo, resulting in treatment discontinuations in 25% versus 4.2% of patients, respectively. Among these events, grade 3 hyperglycaemia (including diabetes mellitus, insulin resistance and metabolic syndrome) was observed in 32.7% of patients receiving alpelisib.
These findings confirm the feasibility and efficacy of targeting PI3Kα using alpelisib in the approximately 40% of patients with PIK3CA-mutant advanced-stage HR+, HER2– breast cancer and confirm the role of PIK3CA mutations as a biomarker. The high risk of hyperglycaemia-related adverse events, which the investigators considered to be an on-target effect, indicates the need for close on-treatment monitoring.
References
Original article
André, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N. Engl. J. Med. 380, 1929–1940 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. Alpelisib effective in advanced-stage disease. Nat Rev Clin Oncol 16, 466 (2019). https://doi.org/10.1038/s41571-019-0234-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0234-0